Literature DB >> 12845647

MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components.

Angel Garcia-Lora1, Marisol Martinez, Ignacio Algarra, Jose Juan Gaforio, Federico Garrido.   

Abstract

Previous reports from our group indicated that the MHC class I phenotype of metastatic lung colonies produced by a mouse fibrosarcoma tumor clone (B9) were, depending on the immune status of the host, MHC class I negative in immunocompetent mice and MHC class I positive in immunodeficient athymic nude/nude mice. Now we report the identification of the molecular alterations responsible for the changes of MHC class I molecules in both situations. Metastatic nodes were analyzed for the mRNA level of H-2 class I and beta2-microglobulin genes, and several gene components of the major histocompatibility complex (MHC) class I antigen-processing machinery (APM). These included the genes coding for the low-molecular-weight proteins LMP2, LMP7, LMP10, the transporter associated with antigen processing (TAP-1, TAP-2), and calnexin, calreticulin, tapasin, PA-28-alpha, PA-28-beta, ERP-59 and ER-60. Analyses with RT-PCR showed that TAP-1, TAP2, LMP-2, LMP7, LMP10, tapasin and calnexin mRNA specific for these genes was absent in metastases produced in immunocompetent mice. In contrast, similar techniques with mRNA preparations obtained from metastatic nodes from immunodeficient mice showed that the mRNA expression level of these genes was highly positive. Interestingly, the MHC class I-positive or negative phenotypes of the metastatic colonies correlated with in vivo immunogenicity. H-2 positive metastasis grew more slowly than the H-2 negative ones when injected intrafootpat in syngeneic immunocompetent animals and were finally rejected. These results provide evidence of the role of T cells in immune surveillance against tumors and identify a mechanism targeted by antitumor T lymphocytes to generate MHC class I-negative tumor escape variants. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12845647     DOI: 10.1002/ijc.11241

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  19 in total

1.  Identification of E2F1 as an important transcription factor for the regulation of tapasin expression.

Authors:  Juergen Bukur; Felix Herrmann; Diana Handke; Christian Recktenwald; Barbara Seliger
Journal:  J Biol Chem       Date:  2010-07-27       Impact factor: 5.157

Review 2.  Key mechanisms involved in ionizing radiation-induced systemic effects. A current review.

Authors:  Ifigeneia V Mavragani; Danae A Laskaratou; Benjamin Frey; Serge M Candéias; Udo S Gaipl; Katalin Lumniczky; Alexandros G Georgakilas
Journal:  Toxicol Res (Camb)       Date:  2015-08-11       Impact factor: 3.524

3.  Are changes in HLA Ags responsible for leukemia relapse after HLA-matched allogeneic hematopoietic SCT?

Authors:  A Hamdi; K Cao; L M Poon; F Aung; S Kornblau; M A Fernandez Vina; R E Champlin; S O Ciurea
Journal:  Bone Marrow Transplant       Date:  2015-01-26       Impact factor: 5.483

4.  NLRC5 expression in tumors and its role as a negative prognostic indicator in stage III non-small-cell lung cancer patients.

Authors:  Xiaoyu Li; Fuchun Guo; Yongmei Liu; Hui-Jiao Chen; Feng Wen; Binwen Zou; Dan Li; Qin Qin; Xiaoke Liu; Yali Shen; Yongsheng Wang
Journal:  Oncol Lett       Date:  2015-07-08       Impact factor: 2.967

5.  Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients.

Authors:  Fatima W Khwaja; Matthew S Reed; Jeffrey J Olson; Brian J Schmotzer; G Yancey Gillespie; Abhijit Guha; Morris D Groves; Santosh Kesari; Jan Pohl; Erwin G Van Meir
Journal:  J Proteome Res       Date:  2007-02       Impact factor: 4.466

Review 6.  MHC heterogeneity and response of metastases to immunotherapy.

Authors:  Ignacio Algarra; Federico Garrido; Angel M Garcia-Lora
Journal:  Cancer Metastasis Rev       Date:  2021-04-15       Impact factor: 9.264

Review 7.  Epigenetic mechanisms of tumor resistance to immunotherapy.

Authors:  Natalia Arenas-Ramirez; Dilara Sahin; Onur Boyman
Journal:  Cell Mol Life Sci       Date:  2018-08-23       Impact factor: 9.261

8.  Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumours.

Authors:  Jasper Manning; Marie Indrova; Barbora Lubyova; Hana Pribylova; Jana Bieblova; Jiri Hejnar; Jana Simova; Tana Jandlova; Jan Bubenik; Milan Reinis
Journal:  Immunology       Date:  2007-08-28       Impact factor: 7.397

9.  Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination.

Authors:  Antonia Busse; Anne Letsch; Carmen Scheibenbogen; Anika Nonnenmacher; Sebastian Ochsenreither; Eckhard Thiel; Ulrich Keilholz
Journal:  J Transl Med       Date:  2010-01-21       Impact factor: 5.531

Review 10.  Testing the theory of immune selection in cancers that break the rules of transplantation.

Authors:  Ariberto Fassati; N Avrion Mitchison
Journal:  Cancer Immunol Immunother       Date:  2009-12-22       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.